Engineered Outer Membrane Vesicles as DNA Vaccine Delivery Vehicles
工程化外膜囊泡作为 DNA 疫苗递送载体
基本信息
- 批准号:7232441
- 负责人:
- 金额:$ 18.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-05-15 至 2008-04-30
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAffinityAntigen-Presenting CellsAntigensAreaBacteriaBindingCaliberCell membraneCellsCharacteristicsClinicClinicalDNADNA VaccinesDNA deliveryDataDendritic CellsDevelopmentDigestionDiseaseDoseEndocytosisEngineeringEnzymesExploratory/Developmental GrantFaceFosteringFutureGenesGenetic EngineeringGram-Negative BacteriaHIVImmune responseImmunizationInvestigationLifeLigandsLiteratureMammalian CellMarshalMembraneMethodologyMethodsModelingMolecular StructureMutateMutationNatureNuclearNumbersPathway interactionsPatientsPhagocytosisPlasmidsPolylysinePolysaccharidesProteinsRangeRateResearchResearch PersonnelResearch Project GrantsResortRoleSurfaceSystemTranslationsTuberculosisUnited States Food and Drug AdministrationVaccinationVaccinesValidationVesicleViralViral VectorWorkbasecellular engineeringclinically relevantcost effectiveexperiencegene therapy clinical trialin vivoleukemiamacrophagenovel vaccinespathogenperiplasmplasmid DNApolyhistidinepreventprogramsprotein aminoacid sequenceresponsestatisticstooltraffickingvaccine deliveryvectorzeta potential
项目摘要
DESCRIPTION (provided by applicant): BACKGROUND: The low immune response to DNA vaccines remains a challenge to their potential clinical use, and the development of new delivery strategies continues to be an area of significant effort. One clinically utilized strategy to enhance the potency of protein and polysaccharide vaccines is to deliver the antigens via bacterial "outer membrane vesicles", or OMVs, which are vesicles constitutively produced by gram-negative bacteria. OMVs are used by bacteria in nature as protein, and potentially DNA, delivery vehicles. The objective of this R21 exploratory research grant is to definitively determine if OMVs can be engineered to deliver plasmid-based DNA vaccines to mammalian antigen presenting cells. HYPOTHESIS: OMV characteristics can be engineered to enhance the delivery of plasmid-based DNA vaccines to mammalian antigen presenting cells. SPECIFIC AIMS: 1) To engineer, and quantitatively evaluate, the surface of plasmid-containing OMVs to maximize their non-specific binding to mammalian cell membranes, and 2) To engineer, and quantitatively evaluate, the surface of plasmid-containing OMVs to facilitate their release from acidic subcellular vesicles. The zeta potential of OMVs is approximately -40 mV which reduces their binding affinity to mammalian cell membranes. To increase the association of OMVs with mammalian cells, and increase the rate of internalization by non- specific endocytosis or phagocytosis, the surface of the OMVs will be engineered to possess sequences of polylysine to create OMVs with positive zeta potentials. Internalization of macromolecular structures by endocytosis/phagocytosis leads to their sequestration within acidic compartments and digestion by lysosomal enzymes. To facilitate the escape of OMVs from the lysosomal trafficking pathway, the surface of the OMVs will be engineered to possess sequences of polyhistidine to disrupt the membrane of acidic vesicles. Validation of the hypothesis will support the future engineering of OMVs with more intricate characteristics, such as cell specific ligands, fusogenic proteins and conformational protein adjuvants.
描述(由申请人提供):背景:对DNA疫苗的免疫力低仍然是对其潜在临床使用的挑战,而新的分娩策略的发展仍然是巨大努力的领域。一种临床上利用的策略来增强蛋白质和多糖疫苗的效力,是通过细菌“外膜囊泡”或OMV传递抗原,或者是由革兰氏阴性细菌组成性产生的囊泡。细菌在自然界中用作蛋白质和潜在的DNA递送车。这项R21探索性研究赠款的目的是确定确定是否可以设计OMV以将基于质粒的DNA疫苗传递给哺乳动物抗原呈递细胞。假设:可以设计OMV特性以增强基于质粒的DNA疫苗向哺乳动物抗原呈递细胞的递送。具体目的:1)对含质粒的OMV的表面进行工程和定量评估,以最大化其非特异性与哺乳动物细胞膜的结合,以及2)对工程师进行工程,并进行定量评估,含有质粒的OMV表面以促进它们从酸性亚细胞囊泡中释放。 OMV的ZETA电位约为-40 mV,可降低其与哺乳动物细胞膜的结合亲和力。为了增加OMV与哺乳动物细胞的关联,并通过非特异性内吞和吞噬作用增加了内在化的速率,OMV的表面将被设计为具有多赖氨酸序列,以创建具有正Zeta电位的OMV。通过内吞和吞噬作用对大分子结构的内在化导致它们在酸性区室内隔离,并通过溶酶体酶消化。为了促进OMV从溶酶体运输途径中逃脱,OMV的表面将被设计为具有多组氨酸序列,以破坏酸性囊泡的膜。该假设的验证将支持具有更复杂特征的OMV的未来工程,例如细胞特异性配体,融合蛋白和构象蛋白辅助剂。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mechanistic insight into the TH1-biased immune response to recombinant subunit vaccines delivered by probiotic bacteria-derived outer membrane vesicles.
- DOI:10.1371/journal.pone.0112802
- 发表时间:2014
- 期刊:
- 影响因子:3.7
- 作者:Rosenthal JA;Huang CJ;Doody AM;Leung T;Mineta K;Feng DD;Wayne EC;Nishimura N;Leifer C;DeLisa MP;Mendez S;Putnam D
- 通讯作者:Putnam D
Microbial biosynthesis of designer outer membrane vesicles.
- DOI:10.1016/j.copbio.2014.02.018
- 发表时间:2014-10
- 期刊:
- 影响因子:7.7
- 作者:Baker, Jenny L.;Chen, Linxiao;Rosentha, Joseph A.;Putnam, David;DeLisa, Matthew P.
- 通讯作者:DeLisa, Matthew P.
A Molecularly Complete Planar Bacterial Outer Membrane Platform.
- DOI:10.1038/srep32715
- 发表时间:2016-09-07
- 期刊:
- 影响因子:4.6
- 作者:Hsia CY;Chen L;Singh RR;DeLisa MP;Daniel S
- 通讯作者:Daniel S
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID A PUTNAM其他文献
DAVID A PUTNAM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID A PUTNAM', 18)}}的其他基金
Co-Presentation and Delivery of TLR Agonist Combinations with Subunit Antigens to Pathogen-Match the Immune Response
TLR 激动剂与亚单位抗原组合的共提呈和递送,以匹配病原体的免疫反应
- 批准号:
10464899 - 财政年份:2018
- 资助金额:
$ 18.54万 - 项目类别:
Co-Presentation and Delivery of TLR Agonist Combinations with Subunit Antigens to Pathogen-Match the Immune Response
TLR 激动剂与亚基抗原组合的共提呈和递送,以匹配病原体的免疫反应
- 批准号:
9980271 - 财政年份:2018
- 资助金额:
$ 18.54万 - 项目类别:
Co-Presentation and Delivery of TLR Agonist Combinations with Subunit Antigens to Pathogen-Match the Immune Response
TLR 激动剂与亚单位抗原组合的共提呈和递送,以匹配病原体的免疫反应
- 批准号:
10225567 - 财政年份:2018
- 资助金额:
$ 18.54万 - 项目类别:
Co-Presentation and Delivery of TLR Agonist Combinations with Subunit Antigens to Pathogen-Match the Immune Response
TLR 激动剂与亚基抗原组合的共提呈和递送,以匹配病原体的免疫反应
- 批准号:
9763442 - 财政年份:2018
- 资助金额:
$ 18.54万 - 项目类别:
Effective Mucosal Vaccination through Engineered Outer Membrane Vesicles
通过工程外膜囊泡进行有效的粘膜疫苗接种
- 批准号:
9510636 - 财政年份:2018
- 资助金额:
$ 18.54万 - 项目类别:
Co-Presentation and Delivery of TLR Agonist Combinations with Subunit Antigens to Pathogen-Match the Immune Response
TLR 激动剂与亚单位抗原组合的共提呈和递送,以匹配病原体的免疫反应
- 批准号:
9580295 - 财政年份:2018
- 资助金额:
$ 18.54万 - 项目类别:
Synthetic lubricin biomaterial for osteoarthritis
用于治疗骨关节炎的合成润滑素生物材料
- 批准号:
8904481 - 财政年份:2015
- 资助金额:
$ 18.54万 - 项目类别:
Synthetic Lubricin Mimetics for the Treatment of Osteoarthritis
用于治疗骨关节炎的合成润滑素模拟物
- 批准号:
9068814 - 财政年份:2014
- 资助金额:
$ 18.54万 - 项目类别:
Synthetic Lubricin Mimetics for the Treatment of Osteoarthritis
用于治疗骨关节炎的合成润滑素模拟物
- 批准号:
9270501 - 财政年份:2014
- 资助金额:
$ 18.54万 - 项目类别:
Engineered Outer Membrane Vesicles as DNA Vaccine Delivery Vehicles
工程化外膜囊泡作为 DNA 疫苗递送载体
- 批准号:
7015400 - 财政年份:2006
- 资助金额:
$ 18.54万 - 项目类别:
相似国自然基金
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
面向免疫疗法标志物识别的基于多特征融合的肽与MHC亲和力预测研究
- 批准号:62302277
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
面向多场景应用的药物-靶标结合亲和力预测研究
- 批准号:62371403
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Project 1: The impact of innate immune responses on the development of broadly neutralizing antibodies by vaccination
项目 1:先天免疫反应对通过疫苗接种产生广泛中和抗体的影响
- 批准号:
10731281 - 财政年份:2023
- 资助金额:
$ 18.54万 - 项目类别:
Delivery of anti-bacterial glycan vaccines to cells and subcellular compartments
将抗菌聚糖疫苗递送至细胞和亚细胞区室
- 批准号:
10549647 - 财政年份:2023
- 资助金额:
$ 18.54万 - 项目类别:
Nanotechnology-based platform for the development of next-generation vaccines against opioid use disorder (OUD)
基于纳米技术的平台,用于开发针对阿片类药物使用障碍(OUD)的下一代疫苗
- 批准号:
10751208 - 财政年份:2023
- 资助金额:
$ 18.54万 - 项目类别:
STAT5 tetramerization in autoimmune-mediated neuroinflammation
自身免疫介导的神经炎症中的 STAT5 四聚化
- 批准号:
10627016 - 财政年份:2022
- 资助金额:
$ 18.54万 - 项目类别:
Investigation of Synthetic DNA-based Viral Particles for Spatially Controlled Antigen Presentation
基于 DNA 的合成病毒颗粒空间控制抗原呈递的研究
- 批准号:
10253355 - 财政年份:2021
- 资助金额:
$ 18.54万 - 项目类别: